domingo, 2 de abril de 2017

Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis? - PubMed - NCBI

Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis? - PubMed - NCBI



 2016 Jun;9(2):301-6. doi: 10.1016/j.path.2016.01.009. Epub 2016 Apr 11.

Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis?

Abstract

Genetic testing for a hereditary predisposition to gynecologic cancers has been available clinically since the 1990s. Since then, knowledge of the hereditary contribution to gynecologic cancers has dramatically increased, especially with respect to ovarian cancer. Although knowledge of the number of gynecologic cancer-predisposing genes has increased, the integration of genetic predisposition testing into routine clinical practice has been much slower. This article summarizes the technical and practical aspects of genetic testing in gynecologic cancers, the potential barriers to more widespread access and practice of genetic testing for hereditary predisposition to gynecologic cancers, and the potential solutions to these barriers.

KEYWORDS:

Gene panels; Genetic predisposition; Gynecologic cancer; Multiplex genetic testing

PMID:
 
27241110
 
DOI:
 
10.1016/j.path.2016.01.009

[Indexed for MEDLINE]

No hay comentarios:

Publicar un comentario